CSS
MRNA icon

Cubist Systematic Strategies’s Moderna MRNA Stock Holding History

Cubist Systematic Strategies’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$2.27M Buy
87,700
+8,800
+11% +$245K 0.01% 1486
2025
Q2 		$2.18M Sell
78,900
-237,600
-75% -$6.26M 0.01% 1527
2025
Q1 		$8.97M Sell
316,500
-189,400
-37% -$6.72M 0.05% 538
2024
Q4 		$21M Buy
505,900
+190,100
+60% +$9.09M 0.13% 193
2024
Q3 		$21.1M Buy
315,800
+17,500
+6% +$1.61M 0.13% 175
2024
Q2 		$35.4M Sell
298,300
-32,900
-10% -$4.16M 0.24% 53
2024
Q1 		$35.3M Sell
331,200
-104,200
-24% -$10.5M 0.2% 58
2023
Q4 		$43.3M Buy
435,400
+41,200
+10% +$3.47M 0.28% 18
2023
Q3 		$40.7M Buy
394,200
+83,800
+27% +$9.35M 0.3% 27
2023
Q2 		$37.7M Buy
310,400
+84,200
+37% +$11.2M 0.25% 41
2023
Q1 		$34.7M Buy
226,200
+86,900
+62% +$14.3M 0.21% 45
2022
Q4 		$25M Buy
139,300
+80,000
+135% +$13.1M 0.15% 91
2022
Q3 		$7.01M Sell
59,300
-14,700
-20% -$2.23M 0.04% 760
2022
Q2 		$10.6M Buy
+74,000
New +$10.6M 0.06% 405

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Cubist Systematic Strategies's MRNA Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its Moderna (MRNA) stake by 81% in Q3 2025, selling an estimated $5.67M and leaving 48,641 shares worth $1.26M. The position accounts for 0.01% of the portfolio, ranked #1837.

Cubist Systematic Strategies first reported a position in MRNA in Q2 2019 and has held it in 17 quarters since. The position peaked at $10.2M in Q2 2022. 644 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

  • Cubist Systematic Strategies held 48,641 shares of Moderna worth $1.26M as of Q3 2025.
  • Cubist Systematic Strategies sold 203,368 Moderna shares in Q3 2025, an estimated $5.67M.
  • Moderna made up 0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1837 holding.
  • Cubist Systematic Strategies first reported a position in Moderna in Q2 2019 and has held it in 17 quarters since.
  • Cubist Systematic Strategies's Moderna position peaked at $10.2M in Q2 2022.
  • 644 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.